NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization825.29 mln
Float43.21 mln
Earnings Date05/07/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
31.63
Transformational upside
Relative Strength
77
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-44.07
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cullinan Therapeutics is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for cancer and autoimmune conditions. The company is currently running multiple clinical trials, testing several experimental medicines including targeted therapies for blood cancers, lung cancer, and autoimmune diseases. Cullinan works alongside a number of partners, including Taiho Pharmaceutical and Chongqing Genrix Biopharmaceutical, to bring its treatments to patients. Founded in 2016, the company operates under its current name following a rebranding in 2024.
